The long-term outlook for Sight Sciences is anchored by the commercial expansion of its flagship interventional glaucoma surgical devices and the accelerating adoption of its dry eye treatment procedures following positive reimbursement milestones. While ongoing revenue growth, exceptional gross margins, and expanding international distribution support a constructive trajectory toward cash-flow breakeven, the enterprise continues to navigate operating loss management and medical device market competition.